|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Avalo Therapeutics, Inc (AVTX) |
|
|
$0.43 0.00 (0.00%) as of 4:30 Thu 7/7
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
112,320,000 |
| Market
Cap: |
48.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4301 - $0.4301 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avalo Therapeutics is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology and rare genetic diseases. Co.'s clinical-stage pipeline include: AVTX-002, which is developing for the treatment of non-eosinophilic asthma, inflammatory bowel disease; AVTX-007, which is developing AVTX-007 for the treatment of Still's Disease; AVTX-801, which is a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency; and AVTX-803, which is a L-fucose substrate replacement therapy for the treatment of LADII.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
79,351 |
662,763 |
| Total Buy Value |
$0 |
$0 |
$272,578 |
$643,635 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
18 |
32 |
| Total Shares Sold |
0 |
0 |
5,291,542 |
5,291,542 |
| Total Sell Value |
$0 |
$0 |
$3,199,077 |
$3,199,077 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
4 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boyd Steven |
Director |
– • • |
2021-05-18 |
4 |
B |
$2.33 |
$51,260 |
D/D |
22,000 |
39,100,000 |
3.92 |
7% |
|
| Boyd Steven |
Director |
– • • |
2021-05-17 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
39,078,000 |
2.17 |
8% |
|
| Boyd Steven |
Director |
– • • |
2021-05-17 |
4 |
B |
$2.20 |
$66,000 |
D/D |
30,000 |
39,078,000 |
3.92 |
8% |
|
| Boyd Steven |
Director |
– • • |
2021-05-14 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
39,048,000 |
2.17 |
12% |
|
| Boyd Steven |
Director |
– • • |
2021-05-14 |
4 |
B |
$2.15 |
$275,200 |
D/D |
128,000 |
39,048,000 |
3.92 |
12% |
|
| Boyd Steven |
Director |
– • • |
2021-04-15 |
4 |
A |
$0.00 |
$0 |
I/I |
0 |
38,920,000 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-04-15 |
4 |
OE |
$2.00 |
$12,571,430 |
D/D |
6,285,715 |
38,920,000 |
|
- |
|
| Wilkins H Jeffrey |
Chief Medical OfficerOfficer |
• – – |
2021-03-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,090 |
|
-7% |
|
| Greenway Schond L. |
CFO & TreasurerOfficer |
• – – |
2021-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
-13% |
|
| Boyd Steven |
Director |
– • • |
2021-01-08 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
32,634,285 |
2.17 |
4% |
|
| Boyd Steven |
Director |
– • • |
2021-01-08 |
4 |
B |
$2.60 |
$6,500,000 |
D/D |
2,500,000 |
32,634,285 |
3.92 |
4% |
|
| Neil Garry Arthur |
Chief Scientific Officer |
• – – |
2020-12-10 |
4 |
B |
$2.28 |
$8,199 |
D/D |
3,599 |
77,680 |
2.74 |
-8% |
|
| Harrell James Archie Jr |
Chief Commercial Officer |
• – – |
2020-12-10 |
4 |
B |
$2.28 |
$390 |
D/D |
171 |
28,180 |
2.66 |
-8% |
|
| Sullivan Christopher Ryan |
Interim CFO |
• – – |
2020-12-10 |
4 |
B |
$2.28 |
$11,606 |
D/D |
5,095 |
8,049 |
2.74 |
-8% |
|
| Boyd Steven |
Director |
– • • |
2020-12-03 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
30,134,285 |
2.17 |
2% |
|
| Boyd Steven |
Director |
– • • |
2020-12-03 |
4 |
B |
$2.44 |
$48,800 |
D/D |
20,000 |
30,134,285 |
3.92 |
2% |
|
| Boyd Steven |
Director |
– • • |
2020-11-25 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
30,114,285 |
2.17 |
23% |
|
| Boyd Steven |
Director |
– • • |
2020-11-25 |
4 |
B |
$2.39 |
$35,850 |
D/D |
15,000 |
30,114,285 |
3.92 |
23% |
|
| Boyd Steven |
Director |
– • • |
2020-11-24 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
30,099,285 |
2.17 |
27% |
|
| Boyd Steven |
Director |
– • • |
2020-11-24 |
4 |
B |
$2.40 |
$114,559 |
D/D |
47,733 |
30,099,285 |
3.92 |
27% |
|
| Boyd Steven |
Director |
– • • |
2020-11-23 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
30,051,552 |
2.17 |
28% |
|
| Boyd Steven |
Director |
– • • |
2020-11-23 |
4 |
B |
$2.32 |
$86,459 |
D/D |
37,267 |
30,051,552 |
3.92 |
28% |
|
| Boyd Steven |
Director |
– • • |
2020-09-04 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
30,014,285 |
2.17 |
30% |
|
| Boyd Steven |
Director |
– • • |
2020-09-04 |
4 |
B |
$2.20 |
$220,000 |
D/D |
100,000 |
30,014,285 |
3.92 |
30% |
|
| Boyd Steven |
Director |
– • • |
2020-06-11 |
4 |
B |
$2.44 |
$68,320 |
I/I |
28,000 |
1,128,000 |
2.25 |
-7% |
|
440 Records found
|
|
Page 4 of 18 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
